Evidence map›Paper›PMID 31104495›Full record

ArticleCirculation. Heart failure2019

Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

João Pedro Ferreira, Job Verdonschot, Timothy Collier, Ping Wang, Anne Pizard, Christian Bär, Jens Björkman, Alessandro Boccanelli, Javed Butler, Andrew Clark and 23 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Circulation. Heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02556450 (Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02556450 phase2completednot on this map

Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) "HOMAGE" Programme " Heart OMics in AGing "

TypeinterventionalSponsorACS BiomarkerRan2016 to 2019Enrolled528ConditionsHeart FailureArmsSpironolacton
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Clinical Insights from Proteomics in Heart Failure.Current heart failure reports · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 7 countries.

João Pedro FerreiraUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Job VerdonschotDepartment of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
Timothy CollierLondon School of Hygiene and Tropical Medicine, United Kingdom (T.C.).
Ping WangDepartment of Clinical Genetics, Maastricht University Medical Center, the Netherlands (J.V., P.W.).
Anne PizardUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Christian BärInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Germany (C.B., T.T.).
Jens Björkman
Alessandro BoccanelliCasa di Cura Quisisana, Rome, Italy (A.B.).
Javed ButlerTATAA Biocenter AB, Gothenburg, Sweden (J.B.).
Andrew ClarkHull York Medical School, Castle Hill Hospital, Cottingham, United Kingdom (A.C.).
John G ClelandRobertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, United Kingdom (J.G.C.).
Christian DellesInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, United Kingdom (C.D.).
Javier DiezProgram of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain (J.D., A.G.).
Nicolas GirerdUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Arantxa GonzálezProgram of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain (J.D., A.G.).
Mark HazebroekDepartment of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
Anne-Cécile HubyUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Wouter JukemaDepartment of Cardiology, Leiden University Medical Center, the Netherlands (W.J.).
Roberto LatiniIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy (R.L.).
Joost LeendersACS Biomarker BV, Amsterdam, the Netherlands (J.L.).
Daniel LevyNational Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, MA (D.L.).
Alexandre MebazaaAPHP, University Hospitals Saint Louis Lariboisière, France (A.M., N.V.).
Harald MischakMosaiquesdiagnostics, Hannover, Germany (H.M.).
Florence PinetInserm U1167, Institut Pasteur de Lille, Université de Lille, FHU-REMOD-VHF, France (F.P.).
Patrick RossignolUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (N.S.).
Peter SeverInternational Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, England (P.S.).
Jan A StaessenStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S., Z.-Y.Z.).
Thomas ThumInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Germany (C.B., T.T.).
Nicolas VodovarAPHP, University Hospitals Saint Louis Lariboisière, France (A.M., N.V.).
Zhen-Yu ZhangStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S., Z.-Y.Z.).
Stephane HeymansDepartment of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
Faiez ZannadUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
French Clinical Research Infrastructure Network · FRInstituto de Salud Carlos III · ESImperial College London · GBIstituti di Ricovero e Cura a Carattere Scientifico · ITLeiden University Medical Center · NLTataa Biocenter (Sweden) · SEUniversité Paris Cité · FRUniversity of Glasgow · GBUniversity of London · GBUniversity of Mississippi Medical Center · US

Funding

Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1M
Framingham Project/LevyZ01HL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2008 to 2008
$1.1M
Intramural NIH HHS Z01 HL006001Intramural NIH HHS Z99 HL999999Intramural NIH HHS ZIA HL006001
6 · The paper itself

Abstract

Background Identifying the mechanistic pathways potentially associated with incident heart failure (HF) may provide a basis for novel preventive strategies. Methods and Results To identify proteomic biomarkers and the potential underlying mechanistic pathways that may be associated with incident HF defined as the first hospitalization for HF, a nested-matched case-control design was used with cases (incident HF) and controls (without HF) selected from 3 cohorts (>20 000 individuals). Controls were matched on cohort, follow-up time, age, and sex. Two independent sample sets (a discovery set with 286 cases and 591 controls and a replication set with 276 cases and 280 controls) were used to discover and replicate the findings. Two hundred fifty-two circulating proteins in the plasma were studied. Adjusting for the matching variables age, sex, and follow-up time (and correcting for multiplicity of tests), 89 proteins were found to be associated with incident HF in the discovery phase, of which 38 were also associated with incident HF in the replication phase. These 38 proteins pointed to 4 main network clusters underlying incident HF: (1) inflammation and apoptosis, indicated by the expression of the TNF (tumor necrosis factor)-family members; (2) extracellular matrix remodeling, angiogenesis and growth, indicated by the expression of proteins associated with collagen metabolism, endothelial function, and vascular homeostasis; (3) blood pressure regulation, indicated by the expression of natriuretic peptides and proteins related to the renin-angiotensin-aldosterone system; and (4) metabolism, associated with cholesterol and atherosclerosis. Conclusions Clusters of biomarkers associated with mechanistic pathways leading to HF were identified linking inflammation, apoptosis, vascular function, matrix remodeling, blood pressure control, and metabolism. These findings provide important insight on the pathophysiological mechanisms leading to HF. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02556450.

Indexed as

AgedBiomarkersCase-Control StudiesDisease ProgressionFemaleHeart FailureHumansMaleProteomeProteomicsBiomarkersProteomeapoptosisatherosclerosisblood pressureheart failureproteomics

Identifiers

PMID31104495
PMCPMC8361846
OpenAlexW2946963067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.